Format

Send to

Choose Destination
Transpl Infect Dis. 2013 Apr;15(2):202-7. doi: 10.1111/tid.12051. Epub 2013 Jan 18.

Ureteral stent placement and BK viremia in kidney transplant recipients.

Author information

1
Department of Surgery, Montefiore Medical Center, Bronx, New York 10467-2401, USA. liisekayler@yahoo.com

Abstract

INTRODUCTION:

BK virus (BKV) infection is an important cause of kidney transplant dysfunction. A possible association of double-J ureteral stent placement and BK viremia has been suggested in previous studies; however, risk factors for BK are incompletely understood. We aimed to determine if stent placement is an independent risk factor for BK viremia.

METHODS:

Data were collected on consecutive kidney-only transplant recipients between December 1, 2006 and June 30, 2010. All patients had at least 12 months of follow-up.

RESULTS:

Of 600 consecutive kidney transplants, BK viremia within the first post-transplant year was detected in 93 patients (15.5%); in 70 of these cases, the peak BKV polymerase chain reaction was ≥10,000 copies/mL. By multivariate analysis, significant risk factors for BK viremia were recipient age (P = 0.02) and stent placement (P = 0.03). Stents were placed in 49.2% and removed at a median of 46 days (range: 11-284) post transplantation; removals occurred within 0-30, 30-60, 60-90, 90-120, 120-150, and >150 days post transplantation in 18.4%, 67.2%, 10.5%, 2.4%, 1.0%, and 0.3% of cases, respectively. No association was found of BK viremia with stent duration >46 days (P = 0.70) or by the 6-level groupings (P = 0.92).

CONCLUSIONS:

Although we observed a significant association of BK viremia with stent placement, no dose-dependent effect was seen.

PMID:
23331475
DOI:
10.1111/tid.12051
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center